Browsing by Author "Etik, Digdem Ozer"

Now showing 1 - 20 of 23

ACUTE NECROTIZING PANCREATITIS AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN A PATIENT WITH HEPATOCELLULAR CANCER: CASE REPORT AND REVIEW OF THE LITERATURE
(2019) Ocal, Serkan; Suna, Nuretdin; Etik, Digdem Ozer; Bovyat, Fatih; Selcuk, Haldun; 31574073
Can a 1-day clear liquid diet with a split - dose polyethylene glycol overcome conventional practice patterns during the preparation for screening colonoscopy?
(2019) Etik, Digdem Ozer; Suna, Nuretdin; Gunduz, Cemre; Bostan, Ahmet; Ozdemir, Alperen; Gurel, Bade Yagmur; Yenisekerci, Ezgi; Boyacioglu, Ahmet Sedat; 31258137
Background/Aims: A successful screening colonoscopy is closely linked to the quality of a bowel preparation. In this study, we aimed to determine the impact of a 1-day clear liquid diet (CLD) compared to a 3-day combined diet (CMD) accompanied by a split-dose regimen of polyethylene glycol and electrolyte lavage solution (PEG-ELS) for screening colonoscopy. Materials and Methods: This was a prospective, randomized, endoscopist-blinded study. Patients referred for screening colonoscopy were randomized to four groups as a 1-day CLD+PEG-ELS vs. a 1-day CLD+sulfate free (SF)-PEG-ELS and a 3-day CMD+PEG-ELS vs. a 3-day CMD+SF-PEG-ELS. An assessment of the quality of colon cleaning, tolerability to the preparation, and symptoms related to the preparation were recorded. Results: A total of 506 patients were enrolled in this study. The quality of bowel preparation was significantly inferior in the CMD+PEG-ELS group than CLD+PEG-ELS (p=0.004) and CMD+SF-PEG-ELS groups (p=0.007). There were no statistical differences among the groups in terms of the polyp detection rate. With respect to an easy rating of diet following and the consumption of laxative, there were no significant differences among the four groups. Gastric fullness and nausea/vomiting were pointed out much more, especially in the SF-PEG-ELS users (p=0.008 and p=0.004, respectively). Conclusion: A 1-day CLD was not inferior to a 3-day CMD for colonoscopy preparation in terms of bowel cleaning, the polyp detection rate, and patient tolerance.
Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?
(2019) Etik, Digdem Ozer; Sezer, Semih; Suna, Nuretdin; Oztas, Erkin; Kilic, Zeki Mesut Yalin; 31258136
Background/Aims: The duration of Helicobacter pylori (H. pylori) eradication therapy as a range (e.g., 10-14 days) is an ignored problem. There is no any particular treatment duration described in current guidelines, and the conditions for when to use 10-day therapy vs. 14-day therapy have not been elucidated. The aim of this study is to determine an effective and reliable H. pylori treatment duration in clinical practice. There were four different treatment modalities administered to groups, and success rates were compared. Materials and Methods: Patients were eligible to participate in the study if they had a biopsy-proven H. pylori infection. Each patient was randomly assigned to one of the four treatment groups according to a predetermined sequence: 14-day or 10-day bismuth-containing quadruple therapy (BQT) groups and 14-day or 10-day moxifloxacin-bismuth-combined treatment (MBCT) groups. Results: A total of 216 patients (54 per group) were enrolled. Two-hundred six patients (95.3%) completed therapy. There was no significant difference in the eradication rates between those patients who received 10- and 14-days BQT regimens (p=0.67). The 14-BQT protocol had the highest eradication rate, the MBCT regimes had the highest compliance, and the 10-MBCT protocol had the poorest results for H. pylori eradication. The posttreatment questionnaire on adverse effects identified nausea/vomiting as the most common side effect (35.7%). Conclusion: Overall, the results of our study suggest that shortening the BQT protocol duration to 10 days does not weaken the H. pylori eradication rate. Moreover, quinolone-containing therapies with the lowest eradication rate among the groups should not be offered as a salvage treatment in case of the BQT failure.
Clinical Course of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis after Liver Transplantation
(2018) Dagli, Ulku; Etik, Digdem Ozer; Akdur, Aydincan; Selcuk, Haldun; Hilmioglu, Fatih; Boyacioglu, Sedat; Moray, Gokhan; Haberal, Mehmet; 0000-0003-0664-0976; 0000-0002-4724-0728; 0000-0002-8726-3369; 0000-0002-8445-6413; 0000-0002-6440-5686; 0000-0002-9370-1126; 0000-0003-2498-7287; 0000-0002-3462-7632; S-4068-2018; AAJ-4707-2021; AAA-3068-2021; AAJ-6976-2021; AAJ-4437-2021; AAE-7637-2021; AAE-1041-2021; AAJ-8097-2021
Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center
(2019) Suna, Nuretdin; Etik, Digdem Ozer; Ocal, Serkan; Selcuk, Haldun; 31050621
Objectives: Hepatocellular carcinoma is the most frequent primary malignant tumor of the liver and the third most common cause of all cancer-related mortalities. There is a need to develop new strategies to prevent hepatocellular carcinoma, as the incidence of this cancer continues to increase despite all advancements. In this study, our aim was to determine the effects of propranolol treatment on the incidence of hepatocellular carcinoma in cirrhotic patients waiting for liver transplant. Materials and Methods: We retrospectively reviewed the data of patients waiting for liver transplant with cirrhosis due to various causes registered at the Hepatocellular Carcinoma Surveillance Program between June 2011 and December 2017 in our center. These data were compared between patients using propranolol and those not using propranolol. Results: Of the 231 patients, 135 (58.4%) were male and 96 (41.6%) were female. The mean age was 58.1 +/- 14 years. We noted that 153 of total patients (66.2%) were using propranolol. Three patients (2%) were using 20 mg propranolol, 125 (81.7%) were using 40 mg propranolol, 10 (6.5%) were using 60 mg propranolol, and 15 (9.8%) were using 80 mg propranolol. Of total patients, 36 (15.6%) developed hepatocellular carcinoma, including in 12 patients (7.8%) using propranolol and 24 patients (30.8%) who did not use this agent (P < .001).Thus, the hepatocellular carcinoma frequency was 5.22 times lower in patients receiving propranolol than in those not receiving propranolol. Conclusions: Although causes of cirrhosis and initial stages were similar in both groups using and not using propranolol, incidence of hepatocellular carcinoma was significantly lower in the propranolol group than in the group without propranolol. This result showed that propranolol treatment has a protective effect for hepatocellular carcinoma in patients waiting for liver transplant with cirrhosis.
The Effect of Treatment of Iron Deficiency Anemia on Thyroid Volume
(2019) Etik, Digdem Ozer; Erdogan, Murat Faik
Objective: Iron and iodine, which are the two important micronutrients, are still deficient in a large number of women worldwide. This study aimed to examine the thyroid volumes of iron deficient, anemic women before and after correction of the anemia in a mildly iodine deficient environment. Material and Methods: Sixty six women aged 18-45 years were prospectively enrolled in this study. Inclusion criteria included serum hemoglobin (Hb) level <11.0 g/dL, ferritin level <13 ng/mL, thyroid hormones within normal reference ranges and negative thyroid antibodies. Oral iron supplement (567 mg ferrous sulfate, twice a day) for six months was prescribed and strongly recommended. All patients were re-evaluated at the end of the iron treatment. Results: Initially, the median (minimum/maximum) Hb and ferritin levels of patients were 10.2 g/dL (5.6/11.1) and 3.95 ng/mL (0.44/10.7), respectively. Six months later, median Hb and ferritin values increased significantly to 13.15 g/dL (9.3/15.6) (p<0.001) and 19.575 ng/mL (3.74/79) (p<0.001) respectively. Median thyroid volume decreased significantly from 15.705 mL (7.15/54.2) to 13.212 mL (6.11/52.8) (p<0.001). The patients were grouped according to the improvements in Hb and ferritin levels, initial thyroid gland volume, and response to the treatment. The reduction in thyroid gland size, at the end of the treatment, was more significant in patients with improvement in both Hb and ferritin levels as compared to those with improvement only in Hb levels (p<0.05). Conclusion: Iron may be responsible for efficient organification of iodine, active iodine utilization from thyroglobulin, and control of hyperkinetic blood-flow to the thyroid gland. The findings of this study support that other than iodine, iron supplementation has a significant effect on the regression of thyroid volume in women with iron deficiency anemia.
Efficacy And Safety Of Tenofovir Alafenamide In Hepatitis B Virus-Infected Patients With Chronic Hemodialysis And Renal Transplantation: A Preliminary Result
(2021) Etik, Digdem Ozer; Boyacioglu, Sedat
Efficacy and Tolerability of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in Kidney Transplant Recipients
(2018) Suna, Nuretdin; Etik, Digdem Ozer; Ocal, Serkan; Selcuk, Haldun; Dagli, Ulku; Hilmioglu, Fatih; Boyacioglu, Sedat; Haberal, Mehmet; https://orcid.org/0000-0001-6234-7788; https://orcid.org/0000-0003-3719-9482; https://orcid.org/0000-0002-8445-6413; https://orcid.org/0000-0002-6440-5686; https://orcid.org/0000-0002-9370-1126; https://orcid.org/0000-0002-3462-7632; AAI-8822-2021; ABH-4817-2020; AAJ-6976-2021; AAJ-4437-2021; AAE-7637-2021; AAJ-8097-2021
Endoplasmic Reticulum Stress Response in Non-Alcholic Fatty Liver Disease: Sophisticated Pathways
(2023) Etik, Digdem Ozer; Verdi, Hasibe; Atac, Fatma Belgin; https://orcid.org/0000-0001-6868-2165; V-5499-2017; ABG-9966-2020
Non-alcoholic fatty liver disease comprises a broad spectrum of fat-associated liver conditions that can result in end-stage liver disease and the need for liver transplantation. The multiparallel hypothesis suggests that steatohepatitis is the result of numerous conditions acting in parallel, including form genetic susceptibility, lipotoxicity, disturbed gut microbiata to mitochondrial dysfunction, and endoplasmic reticulum(ER) stress. The unfolded protein response as the ER stress response is coordinated primarily by ER transmembrane stress transducers which is a defensive response initially activates the cell to recover from stress or adapt to stress. It reduces the secretory protein load, enhances protein folding and increases clearance capacity by promoting autophagy and ER-associated degradation. However, if these attempts fail or the ER stress gets prolonged, it will induce cell death programs to eliminate the stressed cells. In recent years, ER stress response has been identified as a crucial mechanism in steatohepatitis by leading improper lipid biosynthesis, inflammation, and autophagy or apoptosis.
Extraordinary biliary variant
(2017) Suna, Nuretdin; Etik, Digdem Ozer; Ocal, Serkan; Selcuk, Haldun; Hilmioglu, Fatih; Boyacioglu, Sedat; 0000-0003-3719-9482; 0000-0002-9370-1126; 0000-0002-6440-5686; 0000-0002-4724-0728; 0000-0002-8445-6413; 0000-0001-6234-7788; 28336501; ABH-4817-2020; AAE-7637-2021; AAJ-4437-2021; AAJ-4707-2021; AAJ-6976-2021; AAI-8822-2021
Gastric outlet obstruction by polypoid tumors
(2018) Suna, Nurettin; Ocal, Serkan; Etik, Digdem Ozer; Boyacioglu, Seda; 29749338
Giant but Silent Lesion of the Stomach in A Geriatric Patient
(2016) Etik, Digdem Ozer; Tumay, Volkan; Aktas, Hikmet; Meric, Mehmet; Zorluoglu, Abdullah; 0000-0002-6206-9332; 0000-0002-4724-0728; 27782902; A-2109-2019; AAJ-4707-2021
Hepatitis C infection in hemodialysis patients: A review
(2015) Etik, Digdem Ozer; Ocal, Serkan; Boyacioglu, Ahmet Sedat; 25937865
Hepatitis C virus (HCV)-related liver disease is a significant cause of morbidity and mortality in patients with end-stage renal disease (ESRD) who is treated with dialysis or kidney transplantation (KT). The survival rate for HCV-infected renal transplant recipients is better than that for HCV-infected hemodialysis patients on transplant waiting lists. Early diagnosis and treatment HCV infection prior to KT prevents complications post-transplantation and reduces mortality. In addition to screening for anti-HCV antibodies and detecting HCV RNA, percutaneous liver biopsy is particularly valuable for assessing the stage of liver damage in HCV-infected patients, because the stage of fibrosis is important determining optimal treatment for HCV. Studies have been demonstrated that with conventional interferon (IFN) monotherapy or pegylated IFN monotherapy are similar efficacy and safety in HCV-infected hemodialysis patients. Sustained viral responses (SVRs) with these monotherapies have ranged approximately 30% to 40%. Limited reports support the use of IFN and ribavirin combination therapy as antiviral treatment for ESRD patients or patients on hemodialysis. Ribavirin can be started at low dose and careful monitoring for side effects. Patients that show SVR after treatment are strong candidates for KT. It is also generally accepted that ESRD patients with decompensated cirrhosis and portal hypertension should be referred to the liver transplant team for consideration of combined liver-KT.
Hepatocellular Carcinoma with Cardiac Cirrhosis After the Fontan Procedure
(2018) Suna, Nuretdin; Etik, Digdem Ozer; Ocal, Serkan; Hilmioglu, Fatih; 0000-0001-6234-7788; 0000-0002-4724-0728; 0000-0002-6440-5686; 0000-0003-3719-9482; 29373356; AAI-8822-2021; AAJ-4707-2021; AAJ-4437-2021; ABH-4817-2020
Liver Transplant Experiences For The Budd-Chiarı Syndrome At Baskent University Transplant Centers
(2021) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Etik, Digdem Ozer; Boyvat, Fatih; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; AAC-5566-2019; F-4230-2011; AAA-3068-2021; AAJ-8097-2021
Management of Hepatocellular Carcinoma: Prevention, Surveillance, Diagnosis, and Staging
(2017) Etik, Digdem Ozer; Suna, Nurettin; Boyacioglu, Ahmet Sedat; 0000-0001-6234-7788; 0000-0002-4724-0728; 0000-0002-9370-1126; 28301996; AAI-8822-2021; AAJ-4707-2021; AAE-7637-2021
More than 600 000 people die from hepatocellular carcinoma each year. Worldwide, research on the disease needs to be intensified in both the medical and pharmaceutical fields, with a focus on providing help to geographic areas where resources are limited. Treatment approaches depend on the stage of the disease at diagnosis and on access to complex treatment regimens. However, advanced disease is not curable, and treating these patients is expensive and only marginally effective for increasing quality-adjusted life-years. Although the Milan criteria are often used to determine which patients will benefit from liver transplantation, many centers have their own criteria for patient selection. According to criteria developed by Baskent University in Ankara, Turkey, patients with hepatocellular carcinoma and a cirrhotic liver but without extrahepatic disease should be candidates for liver transplant when possible, and living-donor liver transplant should be considered as an alternative rescue therapy for many of these patients. Tumor size and number should not be the sole criteria for excluding liver transplant. Although significant vascular invasion and extrahepatic dissemination definitely indicate major tumor dissemination, until sensitive tests for measuring circulating tumor cells are developed, we continue to recommend liver transplant regardless of tumor size and number. Various locoregional therapies for hepatocellular carcinoma are used before transplant to prevent tumor progression and to decrease the risk of recurrence after transplant. In turn, response to locoregional therapy to decrease tumor stage in hepatocellular carcinoma may be an indicator of tumor behavior and may determine a patient's selection for liver transplant. The delivery of healthcare services for hepatocellular carcinoma could be improved by developing centers of excellence. Concentrating medical care in this way can lead to an increased level of expertise so that resections are performed by surgeons who understand liver disease and the limitations of these and other procedures.
Preliminary Results Of The Effectiveness And Safety Of Tenofovir Alefenamide Fumarate Prophylaxis In HBV-Infected Individuals, Who Received Chemo/Immunosuppressive Therapy
(2022) Gunduz, Feyza; Durak, Serdar; Unsal, Yasemin; Demir, Mehmet; Ellik, Zeynep Melekoglu; Yildirim, Abdullah Emre; Mehdiyev, Shahin; Adanir, Haydar; Demirtas, Coskun Ozer; Ucbilek, Enver; Balaban, Yasemin; Koc, Elif Sitre; Etik, Digdem Ozer; Gokcen, Pinar; Ari, Derya; Gokcan, Hale; Yapali, Suna; Ekmen, Nergis; Arslan, Mehmet; Kayhan, Meral Akdogan; Ozdil, Kamil; Sezgin, Orhan; Boyacioglu, Sedat; Simsek, Halis; Tozun, Nurdan; Dincer, Dinc; Idilman, Ramazan
A rare cause of gastric outlet obstruction
(2017) Suna, Nurettin; Ocal, Serkan; Etik, Digdem Ozer; Selcuk, Haldun; Hilmioglu, Fatih; Boyacioglu, Sedat; 0000-0001-6234-7788; 0000-0003-3719-9482; 0000-0002-8445-6413; 0000-0002-4724-0728; 0000-0002-6440-5686; 0000-0002-9370-1126; 28705787; AAI-8822-2021; ABH-4817-2020; AAJ-6976-2021; AAJ-4707-2021; AAJ-4437-2021; AAE-7637-2021
Real Life Efficacy And Tolerability Of Tenofovir Alafenamde Fumarate In Liver Transplant Recipients: A Multicenter Study
(2022) Gokcan, Hale; Yapali, Suna; Harputluoglu, Murat; Ellik, Zeynep Melekog. Lu; Gokcen, Pinar; Adanir, Haydar; Cosar, Arif Mansur; Durak, Serdar; Ari, Derya; Mehdiyev, Shahin; Koc, Elif Sitre; Guzelbulut, Fatih; Alkim, Huseyin; Ekmen, Nergis; Yildirim, Abdullah Emre; Unsal, Yasemin; Teker, Tufan; Etik, Digdem Ozer; Vatansever, Sezgin; Balaban, Hatice Yasemin; Ozdil, Kamil; Arslan, Mehmet; Kayhan, Meral Akdogan; Gunduz, Feyza; Kiyici, Murat; Boyacioglu, Sedat; Simsek, Halis; Tozun, Nurdan; Dincer, Dinc; Idilman, Ramazan
Real Life Efficacy And Tolerability Of Tenofovir Alafenamide Fumarate In Patients With Hepatitis B Virus-Related Cirrhosis And Liver Transplant Recipients. A-Preliminary Result
(2021) Etik, Digdem Ozer; Boyacioglu, Sedat